Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 5;8(3):89.
doi: 10.3390/biom8030089.

An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift

Eva Rahman Kabir  1 , Shannon Sherwin Moreino  2 , Mohammad Kawsar Sharif Siam  3   4
Affiliations

An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift

Eva Rahman Kabir et al. Biomolecules. .

Abstract

The high demand for and resulting financial success of biopharmaceutical products over the last three decades have seen the door open for close copies of these biological products, also known as biosimilars. This paper seeks to collate all relevant published intelligence with acquired survey data to assess the weight of available evidence that these products hold immense potential for the pharmaceutical industry in terms of their applications and benefits. Biosimilars also pose to be of great promise to the Bangladesh pharmaceutical industry, with the commitment of drastically reducing its dependence on foreign imports of biopharmaceutics to meet local demand. Our questionnaire based survey involved 100 Clinicians, 50 Industry Experts and 100 Academicians. The study found that majority of Industry Experts (72%) and Academicians (63%) shared a different concept of biosimilars opposed to majority of Clinicians (78%). Majority of Academicians (68%) and Industry Experts (61%) also shared a different belief from that of most Clinicians (61%) regarding the need for updating the existing regulatory guidelines. The study also showed that Clinicians (67%), Industry Experts (83%) and Academicians (80%) highlighted the benefit of lower costs of biosimilars. Furthermore, the quality data obtained from the survey results allowed us to evaluate and provide recommendations for stakeholders on the need for increased biosimilar awareness, pharmacovigilance and safety in Bangladesh.

Keywords: Bangladesh pharmaceutical industry; biologics; biosimilars; interchangeability.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Questionnaire screening process for Clinicians.
Figure 2
Figure 2
Questionnaire screening process for Industry Experts.
Figure 3
Figure 3
Questionnaire screening process for Academicians.
Figure 4
Figure 4
Sources of biosimilar awareness for Clinicians in Bangladesh.
Figure 5
Figure 5
Are NCBs synonymous to biosimilar drugs according to Industry Experts.
Figure 6
Figure 6
Are biosimilar products interchangeable with their reference biologics?
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chopra I., Arkells N., Chopra A. Biosimilars: Barriers and Opportunities to Market Access in the United States. Value Health. 2018;21:S93. doi: 10.1016/j.jval.2018.04.625. - DOI
    1. Zalcberg J. Biosimilars are coming: Ready or not. Intern. Med. J. 2018 doi: 10.1111/imj.14033. - DOI - PubMed
    1. WHO Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) [(accessed on 17 April 2017)];2009 Retrieved 17 April 2017. Available online: http://apps.who.int/medicinedocs/en/d/Js19941en.
    1. Markus R., Liu J., Ramchandani M., Landa D., Born T., Kaur P. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community. BioDrugs. 2017;31:175–187. doi: 10.1007/s40259-017-0218-5. - DOI - PMC - PubMed
    1. Danne T., Heinemann L., Bolinder J. New Insulins, Biosimilars, and Insulin Therapy. Diabetes Technol. Ther. 2017;19 doi: 10.1089/dia.2017.2505. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources